News

Kesin Pharma Corporation, a pharmaceutical company focused on innovative Specialty brands and Unit Dose formulations, announced that the U.S. Food and Drug Administration (FDA) has…
Read More...

MBrace Therapeutics, Inc. (“MBrace”), a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates…
Read More...

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, and Absci Corporation, a generative AI drug creation company, announced a drug discovery partnership…
Read More...

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. and Royalty Pharma plc, announced a collaboration to further accelerate the clinical…
Read More...

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, announced…
Read More...

Telix announces that the first patient has been dosed in the Company’s Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting…
Read More...

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announced the close of a €129 million ($138…
Read More...

Valneva SE, a specialty vaccine company, announced that the U.S. Food and Drug Administration (FDA) has approved IXCHIQ, Valneva’s single-dose, live-attenuated vaccine indicated for the…
Read More...

AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the…
Read More...

Takeda announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric…
Read More...

Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, announced that they have updated the focus of…
Read More...

OrsoBio, Inc. announced the successful completion of a $60 million Series A financing, bringing the total capital raised by the Company to $97 million. The financing, which will support…
Read More...

Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced $40 million in Series A extension funding committed by Apple Tree Partners…
Read More...

Takeda announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who…
Read More...

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and Nephron Pharmaceuticals, Inc. (Nephron), a leading manufacturer of sterile injectable drugs announced the…
Read More...

Landmark Bio, a collective endeavor bringing together leaders in industry, academia, and research hospitals to accelerate development and industrialization of next-generation genomic…
Read More...

AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in…
Read More...

Aldeyra Therapeutics, Inc., a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, announced that it has entered…
Read More...

Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies, announced the closing of a CHF25 million Series C financing led by Pureos…
Read More...

Prelude Therapeutics Incorporated and AbCellera announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for…
Read More...